Presentation - What to control? CQAs and CPPs
4 |What to control?, BWP Workshop on Setting Specifications | Thomas Stangler, September 9th, 2011. ICH Q7. Validation: “Defining the API in terms of its critical product attributes“
Download Presentation - What to control? CQAs and CPPs
Information
Domain:
Source:
Link to this page:
Documents from same domain
Q12 Step 2b Technical and regulatory …
www.ema.europa.euICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36
Guideline on good pharmacovigilance practices …
www.ema.europa.eu9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)
Guideline on good pharmacovigilance practices (GVP)
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25
Guideline on good pharmacovigilance practices …
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November
Guideline on good pharmacovigilance practices …
www.ema.europa.euharmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product
European Medicines Agency
www.ema.europa.eu© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline
products1/traditional herbal medicinal products
www.ema.europa.euThere is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already
Q7 Q&A - good manufacturing practice for active ...
www.ema.europa.euICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37
Related documents
Fetal cell detection FINAL - API Paperless …
www.api-pt.comAmerican Proficiency Institute – 2014 1st Test Event EDUCATIONAL COMMENTARY – FETAL CELL DETECTION AND QUANTIFICATION (cont.) When the result of the screening test is negative, 1 dose of RhIG is still given to the D-negative mother.
Publication Droplet Digital PCR: Publications List …
www.bio-rad.comClick icon to read online article. 2015 Albano F et al. (2015). Absolute quantification of the pretreatment PML-RARA transcript defines the relapse risk
1. CURRENT STATUS AND NEW TRENDS IN …
www.bvv.sld.cu1 VacciMonitor 2009; Vol. 18 Año 1 Suppl. 1 ABSTRACTS Traditionally, animal models have played a significant role in quality control of vaccines.
Regulatory Considerations for Peptide Drug Products
www.gphaonline.orgRegulatory Considerations for Peptide Drug Products Larisa C. Wu Peptide Team OGD/CDER/FDA 2013 GPhA/FDA CMC Workshop June 5, 2013 This presentation reflects the views of the author and
Guidance for Industry - Validation and Compliance …
www.labcompliance.deJ:/guidance/2396dft.doc 08/29/00 Guidance for Industry Analytical Procedures and Methods Validation Chemistry, Manufacturing, and Controls Documentation
Annex 1 WHO guidelines on nonclinical evaluation …
www.who.int36 E Immunogenicity Capacity of a vaccine to induce antibody-mediated and/or cell-mediated immunity and/or immunological memory. Nonclinical evaluation of vaccines
Methodological considerations: Potency tests for ...
www.who.intMethodological considerations: Potency tests for recombinant adjuvanted RTS,S vaccine Background Adjuvanted recombinant RTS,S-based vaccines have been in clinical evaluation since the late
Related search queries
Fetal cell detection FINAL, Publication Droplet Digital PCR: Publications, Quality control of vaccines, Regulatory Considerations for Peptide Drug Products, Guidance for Industry, Validation, WHO guidelines on nonclinical evaluation, Immunogenicity, Methodological considerations: Potency tests for, Methodological considerations: Potency tests for recombinant